FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955060158> ?p ?o ?g. }

• W2955060158 endingPage "iv22" @default.
• W2955060158 startingPage "iv22" @default.
• W2955060158 abstract "Introduction: To explore optimal dosing strategy of apatinib treatment in advanced gastric cancer, this study was conducted to compare the efficacy and safety of intermittent (5 days on/2 days off schedule) vs continuous apatinib therapy in combination with docetaxel as second-line treatment for advanced gastric cancer. The design of this study was released in ESMO WCGI 2018 Congress. Methods: This was an open-label, randomized, clinical trial. Eligible patients were randomized to receive intermittent or continuous dosing schedule in a ratio of 1:1. In the intermittent dose arm, patients received oral apatinib 500 mg/d for 5 days followed by 2 days off treatment. In the continuous dose arm, patients received oral apatinib 500 mg/d as continuous daily dosing. Docetaxel 60 mg/m2 was administered intravenously to patients on day 1 in a 21-day cycle in both groups. The primary outcome was progression-free survival. The secondary outcomes included tumor response, overall survival, quality of life and safety. Results: Between September 15, 2017 and January 15, 2019, 58 patients (pts) were enrolled, and 54 were eligible for the analysis, 28 in the intermittent dosing group and 26 in the continuous dosing group. The baseline characteristics of the two groups were balanced. The male pts were 18 (64.29%) in intermittent dosing group versus 18 (69.23%) in continuous dosing group. The patients with ECOG PS 0-1 were 28 (100%) versus 24 (92.31%). Twelve pts experienced surgery (42.86%) versus 14 (53.85%), and 6 (22.22%) versus 13 (50.00%) pts had more than 2 metastases. A total of 37 pts were eligible for short-term efficacy evaluation. The best tumor responses were as follows: in the intermittent dosing group, no one achieved complete response (CR), 5 achieved partial response (PR), 8 achieved stable disease (SD) and 7 achieved progressive disease (PD); in the continuous dosing group, 1 achieved CR, 1 achieved PR, 9 achieved SD, and 6 achieved PD. The overall response rate was 25% versus 11.76%, and disease control rate was 65% versus 64.71%. The mPFS were 5.15 months (95% CI, 2.20-6.26) versus 5.44 months (95% CI, 1.64-6.13), P = .65. The mOS was not reached in the intermittent dosing group, and the mOS in continuous dosing group was 9.80 months (95% CI, 3.08-9.80 +), P = .58. There were 2 pts who experienced dose reduction due to toxicities in the two groups, respectively. The incidence of all grade AEs was 95.83% versus 100%. The incidence of non-hematological AEs was 66.67% versus 100%, and the difference was statistically significant (P = .005). The incidence of hematological AEs was 40.91% versus 100%, and the difference was statistically significant (P = .005). The incidence of grade≥3 AEs was 2% versus 12.96%. No grade 4 AE was reported in intermittent dosing group, and 1 grade 4 AE was reported in continuous dosing group. The most frequent AEs were hypertension (29.17%), fatigue (33.33%), proteinuria (25%), hand-foot syndrome (20.83%) in intermittent dosing group, and in the continuous dosing group the most frequent AEs were hypertension (42.11%), fatigue (36.84%), proteinuria (31.58%), hand-foot syndrome (36.84%). Conclusion: The efficacy profiles of these two dosing regimens were comparable. Patients who received the intermittent dosing regimen experienced less AEs, especially grade≥3 AEs. Intermittent dose scheduling of apatinib could exhibit similar efficacy and less toxicity, and could be an alternative for advanced gastric cancer in second-line treatment." @default.
• W2955060158 created "2019-07-12" @default.
• W2955060158 creator A5001336604 @default.
• W2955060158 creator A5004062737 @default.
• W2955060158 creator A5005110304 @default.
• W2955060158 creator A5007542358 @default.
• W2955060158 creator A5013368549 @default.
• W2955060158 creator A5014162279 @default.
• W2955060158 creator A5018178302 @default.
• W2955060158 creator A5019210696 @default.
• W2955060158 creator A5019246084 @default.
• W2955060158 creator A5030191700 @default.
• W2955060158 creator A5035326805 @default.
• W2955060158 creator A5045488445 @default.
• W2955060158 creator A5049570118 @default.
• W2955060158 creator A5061084006 @default.
• W2955060158 creator A5061801182 @default.
• W2955060158 creator A5073346815 @default.
• W2955060158 date "2019-07-01" @default.
• W2955060158 modified "2023-10-13" @default.
• W2955060158 title "Efficacy and safety of intermittent dosing schedule of apatinib for advanced gastric cancer in second-line setting" @default.
• W2955060158 doi "https://doi.org/10.1093/annonc/mdz155.081" @default.
• W2955060158 hasPublicationYear "2019" @default.
• W2955060158 type Work @default.
• W2955060158 sameAs 2955060158 @default.
• W2955060158 citedByCount "2" @default.
• W2955060158 countsByYear W29550601582020 @default.
• W2955060158 countsByYear W29550601582021 @default.
• W2955060158 crossrefType "journal-article" @default.
• W2955060158 hasAuthorship W2955060158A5001336604 @default.
• W2955060158 hasAuthorship W2955060158A5004062737 @default.
• W2955060158 hasAuthorship W2955060158A5005110304 @default.
• W2955060158 hasAuthorship W2955060158A5007542358 @default.
• W2955060158 hasAuthorship W2955060158A5013368549 @default.
• W2955060158 hasAuthorship W2955060158A5014162279 @default.
• W2955060158 hasAuthorship W2955060158A5018178302 @default.
• W2955060158 hasAuthorship W2955060158A5019210696 @default.
• W2955060158 hasAuthorship W2955060158A5019246084 @default.
• W2955060158 hasAuthorship W2955060158A5030191700 @default.
• W2955060158 hasAuthorship W2955060158A5035326805 @default.
• W2955060158 hasAuthorship W2955060158A5045488445 @default.
• W2955060158 hasAuthorship W2955060158A5049570118 @default.
• W2955060158 hasAuthorship W2955060158A5061084006 @default.
• W2955060158 hasAuthorship W2955060158A5061801182 @default.
• W2955060158 hasAuthorship W2955060158A5073346815 @default.
• W2955060158 hasBestOaLocation W29550601581 @default.
• W2955060158 hasConcept C121608353 @default.
• W2955060158 hasConcept C126322002 @default.
• W2955060158 hasConcept C141071460 @default.
• W2955060158 hasConcept C197934379 @default.
• W2955060158 hasConcept C2777288759 @default.
• W2955060158 hasConcept C2780668389 @default.
• W2955060158 hasConcept C2781190966 @default.
• W2955060158 hasConcept C71924100 @default.
• W2955060158 hasConceptScore W2955060158C121608353 @default.
• W2955060158 hasConceptScore W2955060158C126322002 @default.
• W2955060158 hasConceptScore W2955060158C141071460 @default.
• W2955060158 hasConceptScore W2955060158C197934379 @default.
• W2955060158 hasConceptScore W2955060158C2777288759 @default.
• W2955060158 hasConceptScore W2955060158C2780668389 @default.
• W2955060158 hasConceptScore W2955060158C2781190966 @default.
• W2955060158 hasConceptScore W2955060158C71924100 @default.
• W2955060158 hasLocation W29550601581 @default.
• W2955060158 hasOpenAccess W2955060158 @default.
• W2955060158 hasPrimaryLocation W29550601581 @default.
• W2955060158 hasRelatedWork W2791178278 @default.
• W2955060158 hasRelatedWork W2804571292 @default.
• W2955060158 hasRelatedWork W2809652040 @default.
• W2955060158 hasRelatedWork W2891525318 @default.
• W2955060158 hasRelatedWork W2891731013 @default.
• W2955060158 hasRelatedWork W2898271578 @default.
• W2955060158 hasRelatedWork W3080253259 @default.
• W2955060158 hasRelatedWork W3178724038 @default.
• W2955060158 hasRelatedWork W3188284391 @default.
• W2955060158 hasRelatedWork W3203929545 @default.
• W2955060158 hasVolume "30" @default.
• W2955060158 isParatext "false" @default.
• W2955060158 isRetracted "false" @default.
• W2955060158 magId "2955060158" @default.
• W2955060158 workType "article" @default.